Discussion
The effectiveness of ASCT relies, in part, on the ability to collect an adequate number of HSPCs. The ‘ideal’ HSPC mobilization regimen would be rapid, robust, reliable, well tolerated and capable of safely mobilizing an optimal number of CD34In this international, phase 3, multicenter, randomized, double-blind, placebo-controlled trial, patients were representative of the typical MM population undergoing ASCT in the current era, with a median age of 63 years and 70% of patients receiving lenalidomide-containing induction therapy. Despite the presence of these risk factors for poor HSPC mobilization, 92.5% of patients treated with one injection of motixafortide + G-CSF collected ≥6 × 10Randomized controlled trials (RCTs) comparing the efficacy of G-CSF alone, chemotherapy + G-CSF, plerixafor + G-CSF and motixafortide + G-CSF to mobilize optimal HSPC numbers (≥6 × 10There is also an increasing appreciation of the immunophenotypic and transcriptional heterogeneity of CD34The clinical implications of the observed immunophenotypic and transcriptional heterogeneity within CD34In conclusion, the upfront use of a single injection of motixafortide added to G-CSF resulted in rapid, robust and reliable mobilization of optimal numbers of CD34